Why the study?
Controversy persists regarding the timing of early dual antiplatelet therapy in non-ST-segment elevation acute coronary syndrome, particularly concerning coronary artery bypass graft surgery accessibility.
Does the timing of dual antiplatelet therapy affect outcomes and CABG accessibility in patients with acute coronary syndrome?
Does the timing of dual antiplatelet therapy affect outcomes and CABG accessibility in patients with acute coronary syndrome?
Delaying dual antiplatelet therapy until after coronary angiography in NSTEMI may improve the accessibility of coronary artery bypass grafting.
Answers are grounded in this paper and cite their sources.
Supports early DAPT in STEMI with PCI; leaves open optimal timing pending higher-level trials.
The feasibility of dual antiplatelet therapy as early as possible in patients with ST-segment elevation acute coronary syndrome, where percutaneous coronary intervention is recommended, has been proven: it improves treatment outcomes by reducing the risk of adverse ischemic events, including stent thrombosis and myocardial infarction.This article provides a detailed analysis of the evidence data and current recommendations on the validity and timing of dual antiplatelet therapy for acute coronary syndrome. The emphasis is made on the controversy regarding the early dual antiplatelet therapy in non-ST-segment elevation acute coronary syndrome. The rationale for using dual antiplatelet therapy only after coronary angiography and determining the revascularization strategy is described, which should increase the accessibility of coronary artery bypass graft surgery for patients.
No takes yet. Share an insight, caveat, or question.
Головина et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: